Rodolpho Campos Braga

Rodolpho Campos Braga

Auto-generated profile, based on publicly available information

Rodolpho Campos Braga

InsilicAll Ltda

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2015 in Molecular Informatics
Verified
Journal Article
Closed access
PDF file
RBRodolpho C. Braga
Rodolpho C. Braga
VAVinicius Alves
Vinicius Alves
MSMeryck F. B. Silva
Meryck F. B. Silva
EMEugene Muratov
Eugene Muratov
DFDenis Fourches
Denis Fourches
CACarolina Andrade
Carolina Andrade

1 April 2006 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HSHélio A Stefani
Hélio A Stefani
COCarlindo B. Oliveira
Carlindo B. Oliveira
RARoberta B. Almeida
Roberta B. Almeida
CPClaudio Martin Pereira Pereira
Claudio Martin Pereira Pereira
RBRodolpho C. Braga
Rodolpho C. Braga
CNCristina Nogueira
Cristina Nogueira

28 June 2016 in Green Chemistry
Verified
Journal Article
Closed access
PDF file
VAVinicius Alves
Vinicius Alves
EMEugene N. Muratov
Eugene N. Muratov
SCStephen J. Capuzzi
Stephen J. Capuzzi
RPRegina Politi
Regina Politi
YLYen Low
Yen Low
ATAlexander Tropsha
Alexander Tropsha
Integrative approach for safety assessment of new chemicals by combining structural alerts and QSAR models.

1 September 2011 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
LSL.G. Souza
L.G. Souza
ESE.J. Silva
E.J. Silva
AMA.L.L. Martins
A.L.L. Martins
MMM.F. Mota
M.F. Mota
RBR.C. Braga
R.C. Braga
RMRicardo Neves Marreto
Ricardo Neves Marreto

12 June 2006 in Synlett
Verified
Journal Article
Closed access
PDF file
ABAntonio Braga
Antonio Braga
DLDiogo S. Lüdtke
Diogo S. Lüdtke
FVFabrício Vargas
Fabrício Vargas
RBRodolpho C. Braga
Rodolpho C. Braga
Chiral selenium-containing compounds have found growing application in asymmetric catalysis over the past few years. The large majority of these ligands are derived from readily available chiral amino alcohols in a few high-yielding synthetic steps. The advantages of using these compounds are described, ­particularly those regarding ready accessibility, modular nature, formation of strong bonds with soft metals and more rarely with hard ones. By using an appropriate electrophilic or nucleophilic organoselenium fragment, novel chiral organoselenium catalysts or ligands were designed from chiral aziridines, oxazolines, ferrocenes, etc. High regioselectivity and enantioselectivity were achieved through the four following techniques: the enantioselective copper-catalyzed conjugate addition of organometallic reagents to enones, the diorganozinc addition to aldehydes, palladium-catalyzed enantioselective allylic alkylation and asymmetric hydrosilylation or transfer hydrogenations of ketones.

1 May 2013 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
RBRodolpho C. Braga
Rodolpho C. Braga
CACarolina Andrade
Carolina Andrade
Pharmacophore approaches have evolved to be one of the most successful tools in drug discovery, especially since the past two decades. 3D pharmacophore methods are now commonly used as part of more complex workflows in drug discovery campaigns, and have been successfully and extensively applied in virtual screening (VS) approaches. This review provides a perspective of how to assess the performance of 3D pharmacophore models to be used in VS. Since 3D VS protocols are in general assessed by their ability to discriminate between active and inactive compounds, we summarize the impact of the composition and preparation of modeling and external sets on the outcome of evaluations. Moreover, we highlight the significance of both classic enrichment parameters and advanced descriptors for the performance of 3D pharmacophore-based virtual screening methods.